• Radiation Oncology Journal
• /
• 제2권2호
• /
• pp.287-297
• /
• 1984

The normal intracranial structures are relatively resistant to therapeutic radiation, but may react adversely in a variety of ways, and the damage to nerve tissue may be slow in making its appearance, and once damage has occured the patient recovers slowly and incompletly. Therefore, it is important to consider the possibility of either recurrent tumor or late adverse effect in any patient who has had radiotherapy. The determination o( rnorphological/pathological correlation is very important to the therapeutic radiologist who uses CT scans to define a treatment volume, as well as to the clinician who wishes to explain the patient's clinical state in terms of regress, progression, persistence, or recurrence of tumor or radiation-induced edema or necrosis, The authors are obtained as following results ; 1. The field size(whole CNS, large, intermediate, small field) was variable according to the location and extension of tumor and histopathologic diagnosis, and the tatal tumor dose was 4,000 to 6,000 rads except one of recurred case of 9,100 rads. The duration of follow up CT scan was from 3 months to 5 year 10 months. 2, The histopathologic diagnosis of 9cases were glioblastoma multiforme(3 cases), pineal tumor (3), oligodendroglioma (1), cystic astrocytoma (1), pituitary adenoma (1) and their adverse effects after radiation therapy were brain atrophy (4 cases) , radiation necrosis(2), tumor recurrence with or without calcification (2), radiation·induced infarction (1). 3. The recurrent symptoms after radiation therapy of brain tumor were not always the results of regrowth of neoplasm, but may represent late change of irradiated brain. 4. It must be need that we always consider the accurate treatment planning and proper treatment method to reduce undesirable late adverse effects in treatment of brain tumors.

• Journal of Korean Neurosurgical Society
• /
• 제45권5호
• /
• pp.275-283
• /
• 2009

Objective : We retrospectively analyzed survival, local control rate, and incidence of radiation toxicities after radiosurgery for recurrent metastatic brain lesions whose initial metastases were treated with whole-brain radiotherapy. Various radiotherapeutical indices were examined to suggest predictors of radiation-related neurological dysfunction. Methods : In 46 patients, total 100 of recurrent metastases (mean 2.2, ranged 1-10) were treated by CyberKnife radiosurgery at average dose of 23.1 Gy in 1 to 3 fractions. The median prior radiation dose was 32.7 Gy, the median time since radiation was 5.0 months, and the mean tumor volume was $12.4cm^3$. Side effects were expressed in terms of radiation therapy oncology group (RTOG) neurotoxicity criteria. Results : Mass reduction was observed in 30 patients (65%) on MRI. After the salvage treatment, one-year progression-free survival rate was 57% and median survival was 10 months. Age(<60 years) and tumor volume affected survival rate(p=0.03, each). Acute (${\leq}$1 month) toxicity was observed in 22% of patients, subacute and chronic (>6 months) toxicity occurred in 21 %, respectively. Less acute toxicity was observed with small tumors (<$10cm^3$. p=0.03), and less chronic toxicity occurred at lower cumulative doses (<100 Gy, p=0.004). "Radiation toxicity factor" (cumulative dose times tumor volume of <1,000 Gy${\times}cm^3$) was a significant predictor of both acute and chronic CNS toxicities. Conclusion: Salvage CyberKnife radiosurgery is effective for recurrent brain metastases in previously irradiated patients, but careful evaluation is advised in patients with large tumors and high cumulative radiation doses to avoid toxicity.

• 대한방사선치료학회지
• /
• 제17권1호
• /
• pp.9-17
• /
• 2005

목적 : 방사선치료에 있어 치료부위내의 균등한 선량분포는 환자의 치료성적 및 장해를 좌우하는 매우 중요한 인자이다. 이러한 치료부위내의 균등한 선량분포를 얻기 위해 사용하는 여러 가지 방법 중 간단한 Field-in-Field Technique의 유용성을 평가하고 다양한 크기의 전뇌(whole brain)치료 환자에게 적용가능성을 알아보고자 한다. 대상 및 방법 : 전뇌(whole brain)의 일반적인 치료기법인 대향2문조사와 Field-in-Field Technique을 적용했을 때의 선량분포도를 비교하기 위하여 phantom(acryl 16 cm spheral phantom)을 대상으로 치료계획을 수립하였으며, 선량분포평가를 위하여 저감도필름(X-Omat V-film)과 열형광선량계(TLD)를 사용하여 측정하였다. 또한 다양한 두께의 환자20명(대, 중, 소 및 소아-각각 5명)을 대상으로 Field-in-Field Technique의 적용가능성을 평가 하였다 결과 : 전뇌(whole brain)치료에 대향2문조사와 Field-in-Field Technique을 적용한 경우 각각의 치료부위내의 선량분포 및 DVH를 비교한 결과, Field-in-Field Technique을 사용한 경우 고선량(high dose)영역을 $3{\sim}4\%$이하로 줄일 수 있었고, 저감도필름(X-Omat V-film)과 열형광선량계(TLD)에 의한 측정결과 또한 유사한 수치를 얻을 수 있었다. 이러한 Field-in-Field Technique을 다양한 두께의 환자에게 동일하게 적용해도 선량분포의 변화는 $1{\sim}2\%$로 나타났다. 결론 : 전뇌(whole brain)치료에 Field-in-Field Technique를 이용하여 치료계획을 수립하여 적용하면 치료부위내의 균등한 선량분포를 얻을 수 있으므로 추가적인 치료가 필요한 경우 선량합성이 용이하여 쉽게 치료계획을 수립할 수 있었다. 그리고 균등한 선량분포를 얻기 위해 사용하는 wedge filter 및 3D compensator 의 역할을 대체 할 수 있으며, 방사선 치료 시 고선량 영역으로 인해 발생되는 장해를 최소화할 수 있을 것으로 사료된다.

• 한국의학물리학회지:의학물리
• /
• 제34권4호
• /
• pp.41-47
• /
• 2023

Purpose: This study aimed to dosimetrically compare the technique of three-dimensional conformal radiotherapy (3D CRT), which is a traditional prophylactic cranial irradiation method, and the intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) techniques used in the last few decades with the dynamic conformal arc therapy (DCAT) technique. Methods: The 3D CRT, VMAT, IMRT, and DCAT plans were prepared with 25 Gy in 10 fractions in a Monaco planning system. The target volume and the critical organ doses were compared. A comparison of the body V₂, V₅, and V₁₀ doses, monitor unit (MU), and beam on-time values was also performed. Results: In planned target volume of the brain (PTV_Brain), the highest D99 dose value (P<0.001) and the most homogeneous (P=0.049) dose distribution according to the heterogeneity index were obtained using the VMAT technique. In contrast, the lowest values were obtained using the 3D CRT technique in the body V₂, V₅, and V₁₀ doses. The MU values were the lowest when DCAT (P=0.001) was used. These values were 0.34% (P=0.256) lower with the 3D CRT technique, 66% (P=0.001) lower with IMRT, and 72% (P=0.001) lower with VMAT. The beam on-time values were the lowest with the 3D CRT planning (P<0.001), 3.8% (P=0.008) lower than DCAT, 65% (P=0.001) lower than VMAT planning, and 76% (P=0.001) lower than IMRT planning. Conclusions: Without sacrificing the homogeneous dose distribution and the critical organ doses in IMRTs, three to four times less treatment time, less low-dose volume, less leakage radiation, and less radiation scattering could be achieved when the DCAT technique is used similar to conventional methods. In short, DCAT, which is applicable in small target volumes, can also be successfully planned in large target volumes, such as the whole-brain.

• 대한방사선치료학회지
• /
• 제26권2호
• /
• pp.265-272
• /
• 2014

목 적 : 전뇌 방사선 치료 시 산란선으로 인하여 영향을 받는 갑상선의 피폭선량을 감소시키기 위해 차폐체를 사용하여 갑상선의 차폐 효과를 평가하고자 한다. 대상 및 방법 : 갑상선의 피폭선량을 측정하기 위해 선형가속기(Clinac iX. VARIAN, USA)를 이용하여 6 MV X선, 300 cGy를 인체모형팬텀에 대향 2문 조사하였다. 갑상선의 입사표면선량을 측정하기 위해 인체모형팬텀의 10번째 슬라이스 표면에 유리선량계 다섯 개를 1.5 cm 간격으로 위치시킨 후 차폐체 미사용, bismuth 차폐체 사용, 0.5 mmPb 차폐체 사용, 자체 제작한 1.0 mmPb 차폐체를 사용하여 각각 5회씩 측정하여 평균값을 산출하였다. 또한, 같은 위치에서 갑상선 심부선량을 측정하기 위해서 인체모형팬텀의 10번째 슬라이스 2.5 cm 깊이에서 유리선량계 다섯 개를 1.5 cm 간격으로 위치시킨 후 차폐체 미사용, bismuth 차폐체 사용, 0.5 mmPb 차폐체 사용, 자체 제작한 1.0 mmPb 차폐체를 사용하여 각각 5회씩 측정하여 평균값을 산출하였다. 결 과 : 갑상선의 입사표면선량은 차폐체 미사용 시 44.89 mGy로 측정되었고, bismuth 차폐체는 36.03 mGy, 0.5 mmPb 차폐체는 31.03 mGy, 자체 제작한 1.0 mmPb 차폐체는 23.21 mGy로 측정되었다. 또한, 갑상선의 심부선량은 차폐체 미사용 시 36.10 mGy로 측정되었고, bismuth 차폐체는 34.52 mGy, 0.5 mmPb 차폐체는 32.28 mGy, 자체 제작한 1.0 mmPb 차폐체는 25.50 mGy로 측정되었다. 결 론 : 전뇌 방사선 치료 시 방사선 조사면 밖의 영역에서 발생하는 이차 산란 및 누출 선량에 의해 영향을 받는 갑상선에 대하여 차폐체를 사용했을 때 갑상선 심부는 약 11~30%, 갑상선 표면은 약 20~48% 정도의 피폭선량 감소 효과가 나타났다. 따라서 전뇌 방사선 치료 시 갑상선 차폐체를 사용함으로써 갑상선을 효과적으로 보호하며 치료를 시행할 수 있을 것으로 사료된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권12호
• /
• pp.7401-7407
• /
• 2013

Aim: To compare survival outcomes after whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and WBRT plus SRS combination therapy in Korea, by performing a quantitative systematic review. Materials and Methods: We searched 10 electronic databases for reports on Korean patients treated with WBRT or SRS for brain metastases published prior to July 2010. Independent reviewers screened all articles and extracted the data. When a Kaplan-Meier survival curve was available, median survival time and standard errors were calculated. Summary estimates for the outcomes in each study were calculated using the inverse variance random-effects method. Results: Among a total of 2,761 studies, 20 studies with Korean patients (n=1,053) were identified. A combination of 12 studies (n=566) with WBRT outcomes showed a median survival time of 6.0 months (95%CI: 5.9-6.2), an overall survival rate of 5.6% (95%CI: 1-24), and a 6-month survival rate of 46.5% (95%CI: 37.2-56.1). For nine studies (n=412) on SRS, the median survival was 7.9 months (95%CI: 5.1-10.8), and the 6-month survival rate was 63.1% (95%CI: 49.8-74.8). In six studies (n=75) using WBRT plus SRS, the median survival was 10.7 months (95%CI: 4.7-16.6), and the overall and 6-month survival rates were 16.8% (95%CI: 6.2-38.2) and 85.7% (95%CI: 28.3-96.9), respectively. Conclusions: WBRT plus SRS showed better 1-year survival outcome than of WBRT alone for Korean patients with metastatic brain tumors. However, the results of this analysis have to be interpreted cautiously, because the risk factors of patients were not adjusted in the included studies.

• Radiation Oncology Journal
• /
• 제2권1호
• /
• pp.33-39
• /
• 1984

One hundred and twenty patients with brain metastases were seen and evaluated in the Dept. of Therapeutic Radiology, Seoul National University Hospital between 1979 and 1983. Of these, 90 Patients received whole brain irradiation with 2,000 ra4 in 1 week or 3,000 rad in 2 weeks for Palliative Purpose and 30 patients failed to complete the planned treatment. Carcinoma of the lung(44 cases), choriocarcinoma(11 cases), breast(8 cases) were common Primary tumors of 90 patients receiving planned treatment. Symptomatic subjective response was obtained in $92\%$ of Patients and meurologic functional improvement was obtained in $42\%$ of patients. Median survival was 6.4 months in patients with complete treatment an·d less than 2 months in Patients with incomplete treatment, overall survival rate at 1 year and 2 year were $26\%,\;16\%$ in Patients with complete treatment and $8\%,\;0\%$ in patients with incomplete treatment. Primary site, extent of metastases and interval from diagnosis of primary tumor to brain metastases were identified as prognostic factors.

• 대한방사선치료학회지
• /
• 제29권1호
• /
• pp.57-68
• /
• 2017

목 적: 본 연구는 모양이 불규칙하고 손상위험장기(Organ At Risk, OAR)에 매우 인접한 타겟(Target)의 방사선 치료 시, 비동일평면상(Non-coplanar)의 빔(Beam)을 이용한 Fixed-field 세기변조 방사선치료(Intensity Modulated Radiation Therapy, IMRT)와 용적변조회전 방사선치료(Volumetric Modulated Arc Therapy, VMAT) 치료계획의 유용성을 평가 및 비교해 보고자 하였다. 대상 및 방법: 본원에서 True Beam STX(Varian Medical Systems, USA)를 이용하여 전체 두피(Whole Scalp), 부분적 두피(Partial Scalp), 그리고 전체 뇌실(Whole Ventricle)에 방사선 치료를 받은 환자 중 각 부위별로 2명 씩, 총 6명을 대상으로 하였다. VMAT 치료계획 시, Beamlet에 포함되는 OAR의 용적을 최소화하기 위해 Coplanar 또는 Non-coplanar 빔을 이용하였고, Fixed-field IMRT는 6명 모두 2개 이상의 카우치(Couch) 각도를 이용한 Non-coplanar IMRT(이하 ncIMRT)로 치료계획 하였다. 결 과: 양측 수정체, 양측 시신경, 시신경 교차, 그리고 뇌 줄기의 최대선량과 양측 안구와 해마의 평균선량을 측정하였고, 6명 모두 9개의 OAR 중 6개 이상에서 VMAT 치료계획이 ncIMRT보다 1.1배에서 8.2배가량 높은 선량 값을 나타내었다. 전체 두피와 부분적 두피의 치료 시, 20 Gy가 조사되는 뇌의 용적은 VMAT이 ncIMRT의 2배 이상이었고, 전체 뇌실의 치료 시에는 두 치료계획이 큰 차이를 보이지 않았다. 타겟 Coverage는 두 치료계획 모두 $PTV_{100%}=95%$를 만족시켰고, 타겟 내 최대선량과 치료 시 필요한 총 Monitor Unit(MU)은 ncIMRT가 VMAT보다 높았으며 두 치료계획 모두 임상적용을 위한 Gamma test 시행 결과, 2 mm/2 % 조건을 통과하였다. 결 론: 본 연구 결과, ncIMRT는 VMAT에 비해 치료 시 필요한 MU가 높아 치료시간과 장비의 로딩(Loading)을 증가시키므로 치료의 효율성은 다소 떨어지지만, VMAT과 비슷한 타겟 Coverage를 유지하면서, OAR의 선량은 훨씬 감소시키는 것을 알 수 있었다. 따라서 모양이 불규칙하고 OAR에 매우 인접해 있는 타겟의 방사선 치료 시에는 ncIMRT 치료계획을 고려해 볼 필요가 있다고 사료된다.

• Journal of Korean Neurosurgical Society
• /
• 제52권3호
• /
• pp.193-199
• /
• 2012

Objective : The objective of study is to evaluate the incidence of leptomeningeal carcinomatosis (LMC) in breast cancer patients with parenchymal brain metastases (PBM) and clinical risk factors for the development of LMC. Methods : We retrospectively analyzed 27 patients who had undergone surgical resection (SR) and 156 patients with whole brain radiation therapy (WBRT) as an initial treatment for their PBM from breast cancer in our institution and compared the difference of incidence of LMC according to clinical factors. The diagnosis of LMC was made by cerebrospinal fluid cytology and/or magnetic resonance imaging. Results : A total of 27 patients (14%) in the study population developed LMC at a median of 6.0 months (range, 1.0-50). Ten of 27 patients (37%) developed LMC after SR, whereas 17 of 156 (11%) patients who received WBRT were diagnosed with LMC after the index procedure. The incidence of LMC was significantly higher in the SR group compared with the WBRT group and the hazard ratio was 2.95 (95% confidence interval; 1.33-6.54, p<0.01). Three additional factors were identified in the multivariable analysis : the younger age group (<40 years old), the progressing systemic disease showed significantly increased incidence of LMC, whereas the adjuvant chemotherapy reduce the incidence. Conclusion : There is an increased risk of LMC after SR for PBM from breast cancer compared with WBRT. The young age (<40) and systemic burden of cancer in terms of progressing systemic disease without adjuvant chemotherapy could be additional risk factors for the development of LMC.

• Radiation Oncology Journal
• /
• 제12권1호
• /
• pp.33-42
• /
• 1994

1982년부터 1991년까지 경희대학병원 치료방사선과에서 원발성 중추신경계 림프종으로 확진되어 방사선치료를 받은 16명의 환자를 대상으로 치료결과를 후향적으로 분석하였다. 가장 흔한 세포아형은 large, noncleaved cell과 B cell의 immunoblastic 림프종이었으며 측두엽과 심핵부위에 호발하였다. 치료는 환자를 생검 또는 절제술후 전뇌에 40 Gy(range=30-50 Gy)를 방사선 조사하였으며 원발병소에 15-20 Gy를 추가조사하였다. 16명의 환자중 14명은 방사선치료후 2개월에서 49개월 사이에 사망하였으며, 2명은 재발없이 각각 8개월과 22개월째 생존하고 있다. 1년 및 2년생존율은 각각 55.6$ \% $와 34.7$ \% $이었고, 중간 생존기간은 12개월이었다. 16명의 환자중 재발된 11명을 분석하였다. 방사선치료후 원발부위에 재발은 드물었으나 전뇌조사에서 불구하고 다른 부위에서 재발하였다. 재발율은 뇌에서 68.7$ \% $ (l1/16)이고 척추에서 25.0$ \% $(4/16)이었다. 나이, 성별 발생부위, 병소수, 방사선치료선량등은 각각 생존율과 무관하였다. 이와 같은 결과로 중추신경계 림프종은 방사선 치료의 초기반응은 양호하나 통상적인 방사선치료만으로는 조절이 어려운 질환이다. 따라서 분할치료방법에 의한 방사선량 증가와 항암제의 병용으로 중추신경계 림프종에 대한 치료효과를 향상시키리라 기대한다.